• 1
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998: 33: 99103.
  • 2
    Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991: 13: 7016.
  • 3
    Strettell MDJ, Donaldson PT, Thompson LJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997: 112: 202835.
  • 4
    Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994: 19: 60915.
  • 5
    Donaldson PT, Manns MP. Immunogenetics of liver disease. In: BircherJ, BenhamouJ-P, McIntyreN, RizzettoM, RhodesJ, eds. Oxford Textbook of Clinical Hepatology, Vol. 1 Oxford University Press, Oxford, 1999, 173–88.
  • 6
    Becker KG, Simon RM, Bailey-Wilson JE et al. Clustering of non-major histocompatibility complex susceptibility loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998: 95: 997984.
  • 7
    Becker KG. Comparative genetics of type 1 diabetes and autoimmune disease. Diabetes 1999: 48: 13538.
  • 8
    Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000: 174: 2509.
  • 9
    Donaldson PT. Genetics of autoimmune hepatitis. Semin Liver Dis 2002: 22: 35363.
  • 10
    Cookson S, Constantini PK, Clare M et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999: 30: 8516.
  • 11
    Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999: 117: 64552.
  • 12
    Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000: 31: 4953.
  • 13
    Chervonsky AV. Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol 1999: 11: 6848.
  • 14
    Hugot J-P, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001: 411: 599603.
  • 15
    Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001: 411: 6036.
  • 16
    Todd JA. Tackling common disease. Nature 2001: 411: 5379.
  • 17
    Hampe J, Cuthbert A, Croucher PJP et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001: 357: 19258.
  • 18
    Nagata S. Apoptosis by death factor. Cell 1997: 88: 35565.
  • 19
    Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001: 21: 2729.
  • 20
    Wen L, Peakman M, Lobo-Yeo A et al. T-cell directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990: 336: 152730.
  • 21
    Lohr H, Manns M, Kyriatsoulis A et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991: 84: 297302.
  • 22
    Lohr HF, Schaak JF, Gergen G, Fleischer B, Dienes H-P, Meyer zum Buschenfelde K-H. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic active hepatitis of different etiology. Liver 1994: 14: 1616.
  • 23
    Ogawa S, Sakaguchi K, Takaki A et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J Gastroenterol Hepatol 2000: 15: 6975.
  • 24
    Cheng J, Liu C, Koopman WJ, Mountz JD. Characterisation of human Fas gene – exon/intron organisation and promotor region. J Immunol 1995: 154: 123945.
  • 25
    Huang QR, Morris D, Manolios N. Identification and characterisation of polymorphisms in the promoter region of human Apo-1/Fas (CD95) gene. Mol Immunol 1997: 34: 57782.
  • 26
    Huang QR, Danis V, Lassere M, Edmonds J, Manolinos N. Evaluation of a new apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology 1999: 38: 64551.
  • 27
    Huang QR, Teutsch SM, Buhler MM et al. Evaluation of the apo-1/Fas promoter mvaI polymorphism in multiple sclerosis. Mult Scler 2000: 6: 148.
  • 28
    Hiraide A, Imazeki F, Yokosuka O et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005: 100: 13229.
    Direct Link:
  • 29
    Sun T, Zhou Y, Li H et al. FASL-844C polymorphism is associated with increased activation-induced cell death and risk of cervical cancer. J Exp Med 2005: 202: 96774.
  • 30
    Mehrian R, Quismorio FP Jr, Strassmann G et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998: 41: 596602.
  • 31
    Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999: 31: 92938.
  • 32
    Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992: 103: 12905.
  • 33
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983: 85: 7137.
  • 34
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993: 18: 816822.
  • 35
    Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001: 120: 23949.
  • 36
    Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998: 122: 9939.
  • 37
    Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975: 16: 87683.
  • 38
    Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993: 105: 182432.
  • 39
    Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004: 39: 163138.
  • 40
    Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987: 92: 2159.
  • 41
    Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002: 35: 8907.
  • 42
    Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004: 40: 64450.
  • 43
    Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002: 6: 72737.
  • 44
    Lenardo M, Chan FK, Hornung F et al. Mature T lymphocyte apoptosis- immune regulation in a dynamic and unpredicatble antigenic environment. Annu Rev Immunol 1999: 17: 22153.
  • 45
    Siegel RM, Chan FK-M, Chun HJ, Lenardo MJ. The multifaceted role of Fas signalling in immune cell homeostasis and autoimmunity. Nat Immunol 2000: 1: 46975.
  • 46
    Ogasawara J, Watanabe-Fukunaga M, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993: 364: 8069.
  • 47
    Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999: 30: 8115.
  • 48
    Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000: 108: 56774.
  • 49
    Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001: 34: 24853.
  • 50
    Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in the gut and liver. Am J Physiol 2000: 278: 35466.
  • 51
    Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997: 3: 40913.
  • 52
    Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. Immunomodulatory effects of the liver: deletion of activated CD4 effector cells and suppression of interferon-gamma producing cells after intravenous protein immunisation. J Immunol 2002: 169: 240713.
  • 53
    Park S, Murray D, John B, Crispe IN. Biology and significance of T cell apoptosis in the liver. Immunol Cell Biol 2001: 80: 7483.
  • 54
    Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with SLE. J Rheumatol 2002: 29: 11838.
  • 55
    Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998: 102: 53849.
  • 56
    Issa R, Williams E, Trim N et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001: 48: 54857.
  • 57
    Murphy FR, Issa R, Zhou X et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002: 277: 1106976.
  • 58
    Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 1984: 87: 12227.
  • 59
    Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996: 110: 84857.
  • 60
    Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967: 70: 8919.
  • 61
    Vaishnaw AK, Toubi E, Ohsako S et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/Apo-1) mutations. Arthritis Rheum 1999: 42: 183342.
  • 62
    Jackson CE, Fischer RE, Hsu AP et al. ALPS with a defective Fas genotype: influence on penetrance. Am J Hum Genet 1999: 64: 100214.
  • 63
    Rosen A, Casicola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Diff 1999: 6: 612.
  • 64
    Coakley G, Manolios N, Loughran TP Jr, Panayi GS, Lanchbury JS. A Fas promoter polymorphism at position −670 in the enhancer region does not confer susceptibility to Felty’s and large granular lymphocyte syndromes. Rheumatology 1999: 38: 8836.
  • 65
    Nolsoe RL, Kristiansen OP, Sangthongpitag K et al. Complete molecular scanning of the human Fas gene: mutational analysis and linkage studies in families with type 1 diabetes mellitus. Diabetologia 2000: 43: 8008.